The acquisition adds Kezar's pipeline to Aurinia's portfolio, but the CVR structure means future payouts depend on Kezar's clinical milestones. Monitor Kezar's development progress and any CVR-related disclosures for potential upside or impairment.
Price Chart
Executive Summary
Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences via a tender offer and merger. Shareholders received $6.955 per share in cash plus one contingent value right (CVR) per share. The deal closed on May 11, 2026, with 80.24% of Kezar shares tendered, and the remaining shares were acquired in a subsequent merger without a stockholder vote.
Key Facts
- Aurinia completed the acquisition of Kezar Life Sciences for $6.955 per share in cash plus one CVR per share.
- The tender offer expired on May 8, 2026, with 5,927,580 shares (80.24% of outstanding) validly tendered.
- The merger closed on May 11, 2026, under Section 251(h) of the DGCL without a stockholder vote.
- Outstanding in-the-money stock options were cancelled and converted into cash and CVRs; out-of-the-money options were cancelled for no consideration.
- The CVR Agreement was dated May 11, 2026, with Broadridge as Rights Agent and Fortis Advisors as Representative.
Financial Impact
Total cash consideration for the 5,927,580 shares tendered is approximately $41.2 million (5,927,580 × $6.955). Total deal value including remaining shares and option consideration is not disclosed.
Risk Factors
- CVR payouts are contingent on future milestones and may never materialize.
- Integration risks from absorbing Kezar's operations and pipeline.
- Cash outlay for the acquisition may pressure Aurinia's balance sheet.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-020402 |
| Document: 0001140361-26-020402-index-headers.html | 0001140361-26-020402 |
| Document: 0001140361-26-020402-index.html | 0001140361-26-020402 |
| Document: 0001140361-26-020402.txt | 0001140361-26-020402 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $16.13 $16.12 | ▼ −0.06% | ▼ −0.66% | $15.77 (−2.23%) |
Jun 3, 2026 17w ago | Insider Buy | $15.67 $15.80 | ▲ +0.83% | ▲ +1.95% | $15.77 (+0.64%) |
May 11, 2026 20w ago | 8-K | $15.72 $15.78 | ▲ +0.38% | ▲ +0.69% | $15.77 (+0.32%) |
Feb 26, 2026 31w ago | 8-K | $13.97 $14.60 | ▲ +4.51% | ▲ +10.91% | $15.77 (+12.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access